Correlation Between Sutro Biopharma and Lyell Immunopharma

Can any of the company-specific risk be diversified away by investing in both Sutro Biopharma and Lyell Immunopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Sutro Biopharma and Lyell Immunopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Sutro Biopharma and Lyell Immunopharma, you can compare the effects of market volatilities on Sutro Biopharma and Lyell Immunopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Sutro Biopharma with a short position of Lyell Immunopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Sutro Biopharma and Lyell Immunopharma.

Diversification Opportunities for Sutro Biopharma and Lyell Immunopharma

0.91

Correlation Coefficient

Sutro Biopharma  Lyell Immunopharma

Almost no diversification

The 3 months correlation between Sutro and Lyell is 0.91. Overlapping area represents the amount of risk that can be diversified away by holding Sutro Biopharma and Lyell Immunopharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Lyell Immunopharma and Sutro Biopharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Sutro Biopharma are associated (or correlated) with Lyell Immunopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Lyell Immunopharma has no effect on the direction of Sutro Biopharma i.e., Sutro Biopharma and Lyell Immunopharma go up and down completely randomly.

Pair Corralation between Sutro Biopharma and Lyell Immunopharma

Given the investment horizon of 90 days Sutro Biopharma is expected to under-perform the Lyell Immunopharma. But the stock apears to be less risky and, when comparing its historical volatility, Sutro Biopharma is 1.02 times less risky than Lyell Immunopharma. The stock trades about -0.29 of its potential returns per unit of risk. The Lyell Immunopharma is currently generating about -0.25 of returns per unit of risk over similar time horizon. If you would invest  90.00  in Lyell Immunopharma on October 10, 2024 and sell it today you would lose (25.00) from holding Lyell Immunopharma or give up 27.78% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Strong
Accuracy	100.0%
Values	Daily Returns

Sutro Biopharma  vs.  Lyell Immunopharma

Sutro Biopharma

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Sutro Biopharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in February 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Lyell Immunopharma

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Lyell Immunopharma has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unfluctuating performance in the last few months, the Stock's technical and fundamental indicators remain quite persistent which may send shares a bit higher in February 2025. The latest mess may also be a sign of long-standing up-swing for the company institutional investors.

Pair Trading with Sutro Biopharma and Lyell Immunopharma

The main advantage of trading using opposite Sutro Biopharma and Lyell Immunopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Sutro Biopharma position performs unexpectedly, Lyell Immunopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lyell Immunopharma will offset losses from the drop in Lyell Immunopharma's long position.

The idea behind Sutro Biopharma and Lyell Immunopharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.